BIOA Latest Press Releases

-- November 5, 2026 --

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 4:30 PM

-- November 2, 2026 --

BioArctic collaborator Novartis terminates agreement PRNewswire 4:14 PM

-- October 30, 2026 --

BioArctic's Nomination Committee appointed PRNewswire 10:21 AM

-- October 14, 2026 --

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target Globe Newswire 8:00 AM

-- September 25, 2026 --

BioAge Labs to Present at Upcoming Investor Conferences Globe Newswire 4:30 PM

-- September 8, 2026 --

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema Globe Newswire 8:00 AM

-- September 2, 2026 --

BioAge Labs to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 31, 2026 --

Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 PRNewswire 11:57 AM

-- August 5, 2026 --

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 4:50 PM

-- July 14, 2026 --

More than 75% of Leqembi-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC 2026 PRNewswire 11:39 AM

-- June 16, 2026 --

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes